NCT02777099

Brief Summary

The purpose of this study is to determine whether remote ischemic postconditioning (RIPostC) initiates autonomic nervous system response and affects the prognosis in patients with acute ischemic stroke.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2016

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 19, 2016

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2018

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

September 29, 2017

Status Verified

September 1, 2017

Enrollment Period

2.1 years

First QC Date

May 17, 2016

Last Update Submit

September 27, 2017

Conditions

Keywords

remote ischemic postconditioningautonomic functionheart rate variabilityacute ischemic strokeprognosis

Outcome Measures

Primary Outcomes (1)

  • Heart Rate Variabilities

    Heart rate variability (HRV) is one of the most promising markers represent for autonomic function.We assess the changes from baseline heart rate variability to 7days and 30days.

    at the time points of baseline and 7 and 30 days after treatments

Secondary Outcomes (3)

  • National Institutes of Health Stroke Scale(NIHSS)

    at the time points of baseline and 7days after treatments.

  • Modified Rankin scale(mRS)

    at the time points of baseline and 7,30 and 90 days after treatments

  • Barthel Index(BI)

    at the time points of baseline and 7,30 and 90 days after treatments

Other Outcomes (2)

  • Stroke Recurrence

    90 days after treatments

  • Mortality

    90 days after treatments

Study Arms (2)

RIPostC

EXPERIMENTAL

Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning

Procedure: remote ischemic postconditioning

sham RIPostC

SHAM COMPARATOR

Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure. Intervention:Procedure:Sham Remote Ischemic Postconditioning

Procedure: sham remote ischemic postconditioning

Interventions

Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.

Also known as: PIPostC
RIPostC

Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.

Also known as: sham PIPostC
sham RIPostC

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed as ischemic stroke according to the Chinese guideline of diagnosis and treatment of acute ischemic stroke 2010
  • Age between 18 to 85 years old
  • initial ischemic stroke within 14 days or less.
  • National Institutes of Health Stroke Scale (NIHSS)score 0-15
  • Modified Rankin Scale(mRS)score 1-4
  • Informed consent

You may not qualify if:

  • Intravenous or arterial thrombolysis, or revascularization
  • Acute myocardial infarction,atrial fibrillation,arrhythmia,or cardiogenic cerebral embolism
  • Systolic Blood Pressure(SBP)\>200mmHg after medication treatment
  • Plasma fibrinogen\>7g/L
  • Upper limb fracture or percutaneous injury
  • Subclavian artery stenosis
  • With severe cardiac,respiratory,hepatic,and renal dysfunction or malignant tumor
  • Simultaneous participation in another interventional study
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Guangdong Provincial Hospital of Chinese Medicine

Guangzhou, Guangdong, 510120, China

RECRUITING

Related Publications (1)

  • Liang H, Ye R, Zhang X, Ye H, Ouyang W, Cai S, Wei L. Autonomic function may mediate the neuroprotection of remote ischemic postconditioning in stroke: A randomized controlled trial. J Stroke Cerebrovasc Dis. 2023 Aug;32(8):107198. doi: 10.1016/j.jstrokecerebrovasdis.2023.107198. Epub 2023 Jun 15.

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Lin WEI, MD

    Guangdong Provincial Hospital of Traditional Chinese Medicine

    STUDY CHAIR

Central Study Contacts

Miaomiao MO, Bachelor

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2016

First Posted

May 19, 2016

Study Start

January 1, 2016

Primary Completion

February 1, 2018

Study Completion

December 1, 2018

Last Updated

September 29, 2017

Record last verified: 2017-09

Data Sharing

IPD Sharing
Will not share

Locations